Method for determining hair cycle markers

• US 20060204992A1
• Filed: 02/28/2006
• Published: 09/14/2006
• Est. Priority Date: 08/30/2003
• Status: Abandoned Application

• Current Assignee: Henkel KGaA (Henkel AG & Co KGaA)
• Original Assignee: Henkel KGaA (Henkel AG & Co KGaA)
• Inventors: Schlotmann, Kordula, Petersohn, Dirk, Kessler-Becker, Danlala, Holtkotter, Olaf, Giesen, Melanie
• Application Number:
  US11/364,118
• Publication Number:
  US 20060204992A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The invention relates to a method for determining hair cycle markers in vitro, test kits and biochips which are used to determine hair cycle markers and to the use of proteins, mRNA molecules, proteins or fragments thereof as hair cycle markers. The invention also relates to a test method which is used to detect the effectiveness of cosmetic and pharmaceutical active ingredients which influence the hair cycle, in addition to a screening method which is used to identify cosmetic or pharmaceutical active ingredients which influence the hair cycle and to a method for the production of a cosmetic and pharmaceutical preparation which influences the hair cycle.

Claims

1. An in vitro method for determining hair cycle phase in humans, comprising:

a) providing a plurality of genetically encoded markers isolated from hair covered human skin or from human hair follicles which are differentially expressed at an anagenic phase of the hair cycle when compared to expression in cells in the catagenic phase of the hair cycle;

b) obtaining a sample of hair covered skin or human hair follicles;

c) analyzing the sample of b) for the presence and optionally the quantity of at least one genetically encoded molecule which is differentially expressed in anagenic and catagenic hair follicles and

d) designating the sample as comprising healthy cells in the anagenic phase of the cycle if it contains markers which are expressed at higher levels in anagenic hair follicles or cells in regression in the catagenic phase if it contains molecules which are expressed at higher levels in catagenic hair follicles.

2. The method of claim 1 wherein said genetically encoded markers comprise at least one mRNA molecule, at least one protein or polypeptide or fragments thereof.

3. The method of claim 1, wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

434 to SEQ ID NO;

570 or the corresponding gene product and the sample is designated as comprising healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed more strongly in anagenic hair follicles than in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if the sample contains molecules which are expressed more strongly in catagenic hair follicles than in anagenic hair follicles.

4. The method of claim 1 wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

352 to SEQ ID NO;

433 or the corresponding gene product and the sample is designated as comprising healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed more strongly in anagenic hair follicles than in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if the sample contains molecules which are expressed more strongly in catagenic hair follicles than in anagenic hair follicles.

5. The method of claim 1, wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

142 to SEQ ID NO;

351 or the corresponding gene product and the sample is designated as comprising healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed more strongly in anagenic hair follicles than in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if the sample contains molecules which are expressed more strongly in catagenic hair follicles than in anagenic hair follicles.

6. The method of claim 1, wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

105 to SEQ ID NO;

141 or the corresponding gene product and the sample is designated as comprising healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed at least twice as strongly in anagenic hair follicles when compared to expression in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if it contains molecules which are expressed at least twice as strongly in catagenic hair follicles than in anagenic hair follicles.

7. The method of claim 1, wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

43 to SEQ ID NO;

104 or the corresponding gene product and the sample is designated as comprising healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed at least five times more strongly in anagenic hair follicles when compared to expression in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if the sample contains molecules which are expressed at least five times more strongly in catagenic hair follicles than in anagenic hair follicles.

8. The method of claim 1, wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

29 to SEQ ID NO;

42 or the corresponding gene product and the sample is designated as comprising healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed at least 1.3 times more strongly in anagenic hair follicles when compared to expression in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if the sample contains molecules which are expressed at least 1.3 times more strongly in catagenic hair follicles than in anagenic hair follicles.

9. The method of claim 1, wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

13 to SEQ ID NO;

28 or the corresponding gene product and the sample is designated as healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed at twice as strongly in anagenic hair follicles when compared to expression in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if it contains molecules which are expressed at least twice as strongly in catagenic hair follicles than in anagenic hair follicles.

10. The method of claim 1, wherein said sample is assessed for the presence and optionally the quantity of a molecule selected from the group consisting of SEQ ID NO:

1 to SEQ ID NO;

12 or the corresponding gene product and the sample is designated as comprising healthy cells in the anagenic phase of the hair cycle if it contains molecules which are expressed at five times more strongly in anagenic hair follicles when compared to expression in catagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if the sample contains molecules which are expressed at least five times more strongly in catagenic hair follicles than in anagenic hair follicles.

11. A method as claimed in claim 1, comprising

a) quantifying expression levels of at least two molecules in the sample which are differentially expressed in cells from the anagenic phase of the hair cycle when compared to expression levels in the catagenic phase of the hair cycle;

b) determining the expression ratios of said at least two molecules thereby forming an expression quotient; and

c) comparing the expression ratios obtained with those in column 5 of Tables 2 to 6 and designating the sample as comprising healthy cells in the anagenic phase of the hair cycle if the expression ratios observed in the follicles correspond to the ratios observed in anagenic hair follicles or cells in regression in the catagenic phase of the hair cycle if the expression ratios correspond to those observed in catagenic hair follicles.

12. A test kit for determining hair cycle phase in humans, said test kit comprising reagents suitable for performing the method of claim 1.

13. A test kit for determining hair cycle phase in humans, said test kit comprising reagents suitable for performing the method of claim 11.

16. An in vitro method for identifying a pharmaceutically active agent which modulates the hair cycle, comprising

a) providing a sample hair covered human skin or human follicles comprising cells;

b) determining the phase of the hair cycle of said sample as claimed in claim 1;

c) contacting said cells with said agent at least once; and

d) repeating step b) to determine whether said agent alters the phase of the hair cycle.

17. The method of claim 16, wherein said cells are diseased and exhibit an impairment of hair growth.

18. The method of claim 16, wherein said agent stimulates cells to enter the anagen phase of hair growth.

19. The method of claim 16, performed on a biochip.

20. A test kit for identifying a pharmaceutically active agent which modulates the hair cycle, comprising means for carrying out the test method claimed in claim 16.

21. A marker for use in the method of claim 16, selected from the group consisting of at least one molecule or fragment thereof having a Swissprot Accession Number provided in column 8 of Table 8, a Swissprot Accession Number provided in column 9 of Table 7, A Swissprot Accession Number provided in column 9 of Table 9, a UniGene Accession Number in column 7 of Tables 2 to 6, and a Swissprot Accession Number in column 8 of Tables 2 to 6 or the corresponding gene product.

22. A pharmaceutical preparation comprising the agent identified in claim 16 having efficacy against diseases or impairment of hair and its growth in a pharmaceutically acceptable carrier.

14. A biochip for determining the hair cycle phase in human beings in vitro comprising a solid, i.e. rigid or flexible, carrier and a plurality of probes immobilized thereon which are capable of specifically binding to at least one molecule selected from the group consisting of SEQ ID NO:

1 to SEQ ID NO;

570 or the corresponding gene product.

15. A marker for determining hair cycle phase in human beings in vitro, selected from the group consisting of at least one molecule having a Swissprot Accession Number provided in column 8 of Table 8, a Swissprot Accession Number provided in column 9 of Table 7, a Swissprot Accession Number provided in column 9 of Table 9, a UniGene Accession Number provided in column 7 of Tables 2 to 6, and a Swissprot Accession Number in column 8 of Tables 2 to 6.